The programmed death protein 1 (PD-1) and its ligand (PD-L1) represent a well-
characterized immune checkpoint in cancer, effectively targeted by monoclonal antibodies …

Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal …

Glioma stem cells (GSCs) decrease T cells cognition and evade systemic
immunosurveillance via downregulations or defects of major histocompatibility complex …

Histone deacetylases (HDACs), originally described as histone modifiers, have more
recently been demonstrated to target a variety of other proteins unrelated to the chromatin …

Long-standing efforts to identify the multifaceted roles of histone deacetylase inhibitors
(HDACis) have positioned these agents as promising drug candidates in combatting cancer …

Cancer treatment suffers from limitations that have a major impact on the patient's quality of
life and survival. In the case of chemotherapy, the systemic distribution of cytotoxic drugs …

The anti-inflammatory cytokine IL-10 is a key modulator of immune responses. A better
understanding of the regulation of this cytokine offers the possibility of tipping the balance of …

Throughout the process of carcinogenesis, cancer cells develop intricate networks to adapt
to a variety of stressful conditions including DNA damage, nutrient deprivation, and hypoxia …

Melanoma is the deadliest skin cancer, and its incidence has been increasing faster than
any other cancer. Although immunogenic, melanoma is not effectively cleared by host …

APCs are critical in T cell activation and in the induction of T cell tolerance. Epigenetic
modifications of specific genes in the APC play a key role in this process, and among them …